Details
The newly developed [55Co]55Co-DOTATATE imaging agent has emerged as a more accurate and sensitive radiopharmaceutical to aid in the diagnosis of neuroendocrine tumor metastases. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography/computed tomography (PET/CT) imaging with [55Co]Co-DOTATATE resulted in superior image contrast, potentially leading to enhanced detection of metastases as compared with other commonly used radiopharmaceuticals.
|